Published by mark itwired
Posted on September 21, 2021
Remarkable increase in the companion animal ownership and strong growth of development of the veterinary healthcare infrastructure collectively push the sales of companion animal vaccines in global market. Surpassing the revenues worth US$ 2.5 Bn in 2018, global companion animal vaccines market is projected to exhibit a robust CAGR during 2019 – 2029. Measurable rise in the zoonotic disease prevalence will remain a key factor fueling the demand for companion animal vaccines and drugs.
FDA approvals for novel and innovative companion animal vaccines continue to present potential growth opportunities to R&D of companion animal vaccines. For instance, Zoetis received regulatory approval for ProHeart, used for prevention of heartworm diseases caused by Dirofilaria immitis in dogs.
Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1427
Rising demand for efficient monitoring, diagnosis, prevention, and treatment of various diseases among companion animals has instigated the need for novel drug development along with improved understanding of pathogenicity, immunology, and epidemiology for preventing infectious diseases at an unprecedented level.
Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading market players in the companion animal vaccines market. These manufacturers continue to dominate the market landscape of companion animal vaccines by investing heavily in R&D activities to develop and launch therapeutic vaccines for prevention and treatment of various animal diseases. Surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the animal vaccines market growth.
For instance, in August 2018, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics. Moreover, rise in demand for animal vaccines led to the development of multiple new vaccines. For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 for prevention against infectious bronchitis virus (IBV) in animals.
Future Market Insight brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2029. The global companion animal vaccines is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights of the companion animal vaccines market on basis of product type (attenuated live vaccines, conjugated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines), species type (canine, avian, feline) and distribution channel (companion animal hospitals, companion animal hospitals, companion animal research institutes) across seven major regions.
Download Report TOC @ https://www.futuremarketinsights.com/reports/companion-animal-vaccines-market/table-of-content
1.1. Market Outlook
1.2. Analysis and Recommendations
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3.1. Macro-Economic Factors
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity Analysis
3.1.4. Trends
4.1. Regulations- Stages of Vaccine Development & Approval
4.2. EU Veterinary Biologic Regulations
4.3. Mechanism for Veterinary Product Approval
4.4. Companion Animal Vaccines Market Value Chain
4.5. List of Companion Animal Vaccine Manufacturers
5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
5.2.3. Market Value Comparison
The post Companion Animal Vaccines Market Upcoming Challenges & Competitive Strategies 2029 first appeared on Market Research Blog.
Remarkable increase in the companion animal ownership and strong growth of development of the veterinary healthcare infrastructure collectively push the sales of companion animal vaccines in global market. Surpassing the revenues worth US$ 2.5 Bn in 2018, global companion animal vaccines market is projected to exhibit a robust CAGR during 2019 – 2029. Measurable rise in the zoonotic disease prevalence will remain a key factor fueling the demand for companion animal vaccines and drugs.
FDA approvals for novel and innovative companion animal vaccines continue to present potential growth opportunities to R&D of companion animal vaccines. For instance, Zoetis received regulatory approval for ProHeart, used for prevention of heartworm diseases caused by Dirofilaria immitis in dogs.
Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1427
Rising demand for efficient monitoring, diagnosis, prevention, and treatment of various diseases among companion animals has instigated the need for novel drug development along with improved understanding of pathogenicity, immunology, and epidemiology for preventing infectious diseases at an unprecedented level.
Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading market players in the companion animal vaccines market. These manufacturers continue to dominate the market landscape of companion animal vaccines by investing heavily in R&D activities to develop and launch therapeutic vaccines for prevention and treatment of various animal diseases. Surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the animal vaccines market growth.
For instance, in August 2018, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics. Moreover, rise in demand for animal vaccines led to the development of multiple new vaccines. For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 for prevention against infectious bronchitis virus (IBV) in animals.
Future Market Insight brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2029. The global companion animal vaccines is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights of the companion animal vaccines market on basis of product type (attenuated live vaccines, conjugated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines), species type (canine, avian, feline) and distribution channel (companion animal hospitals, companion animal hospitals, companion animal research institutes) across seven major regions.
Download Report TOC @ https://www.futuremarketinsights.com/reports/companion-animal-vaccines-market/table-of-content
1.1. Market Outlook
1.2. Analysis and Recommendations
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3.1. Macro-Economic Factors
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity Analysis
3.1.4. Trends
4.1. Regulations- Stages of Vaccine Development & Approval
4.2. EU Veterinary Biologic Regulations
4.3. Mechanism for Veterinary Product Approval
4.4. Companion Animal Vaccines Market Value Chain
4.5. List of Companion Animal Vaccine Manufacturers
5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
5.2.3. Market Value Comparison
The post Companion Animal Vaccines Market Upcoming Challenges & Competitive Strategies 2029 first appeared on Market Research Blog.
Explore more articles in the Research Reports category
